The activation and differentiation of CD4 + T cells are regulated by three key signaling components from the T cell antigen receptor (TCR) (signal 1), costimulatory molecules (signal 2) and cytokine receptors (signal 3). The signals from cytokine receptors on CD4 + T cells serve an essential role in the lineage 'decision' of helper T cell subsets 1,2 . Binding of the proinflammatory cytokine IL-6 with a complex of the receptor for interleukin 6 (IL-6R) and the signaltransducing receptor gp130 results in the recruitment and activation of the transcription activator STAT3 (refs. 3-5), and that event serves a dominant role in the differentiation of naive CD4 + T cells into IL-17-producing helper T cells (T H 17 cells) by inducing the lineage-specific transcription factor RORγt 6-9 . Signaling via IL-6 can also contribute to the development of T helper type 2 (T H 2) cells in many situations [10] [11] [12] . How IL-6-driven differentiation of CD4 + T cells is modulated and regulated is incompletely understood.
The activation and differentiation of CD4 + T cells are regulated by three key signaling components from the T cell antigen receptor (TCR) (signal 1), costimulatory molecules (signal 2) and cytokine receptors (signal 3). The signals from cytokine receptors on CD4 + T cells serve an essential role in the lineage 'decision' of helper T cell subsets 1, 2 . Binding of the proinflammatory cytokine IL-6 with a complex of the receptor for interleukin 6 (IL-6R) and the signaltransducing receptor gp130 results in the recruitment and activation of the transcription activator STAT3 (refs. 3-5) , and that event serves a dominant role in the differentiation of naive CD4 + T cells into IL-17-producing helper T cells (T H 17 cells) by inducing the lineage-specific transcription factor RORγt [6] [7] [8] [9] . Signaling via IL-6 can also contribute to the development of T helper type 2 (T H 2) cells in many situations [10] [11] [12] . How IL-6-driven differentiation of CD4 + T cells is modulated and regulated is incompletely understood.
The six members of the tumor-necrosis factor (TNF) receptorassociated factor (TRAF) family function as adaptors for members of the TNF receptor superfamily (TNFRSF) by associating with the intracellular domains of those receptors to mediate downstream signaling events [13] [14] [15] . The carboxy-terminal domain of TRAF proteins, which is composed of a coiled-coil leucine-zipper domain followed by a TRAF domain (TRAF-C), contributes to self-oligomerization of the TRAF proteins and their recognition of a variety of cytoplasmic molecules, including members of the TNFRSF. In addition to regulating signaling from members of the TNFRSF [16] [17] [18] , TRAF proteins are also recruited by the Toll-like receptor family and the RIG-I-like receptor family 15, 19 , and other data suggest they also serve important functions in adaptive immunity controlling T cell signaling from the TCR 20, 21 .
Some reports suggest that TRAF proteins can be modulatory in both a positive manner and a negative manner. The regulatory activity of TRAF proteins in T cell signaling has been demonstrated for TRAF1 in the transcription factor NF-κB1 pathway 22 , TRAF2 and TRAF3 in modulating activation of NF-κB2 (refs. 21,23) , and TRAF6 in signaling via the kinases PI(3)K and PKB 24 . TRAF5 is suggested to be both a positive regulator and a negative regulator of T cells 13, [25] [26] [27] [28] . Although TRAF5 is structurally most homologous to TRAF3 (ref. 29) , its molecular function is most similar to that of TRAF2 in the context of TNF-induced activation of NF-κB 30 . In contrast to mice deficient in TRAF2 or TRAF3, which become runted and die prematurely, TRAF5-deficient mice are viable and show no obvious abnormalities 26 . A pronounced T H 2 response is induced in Traf5 −/− CD4 + T cells, and allergic lung inflammation is more exaggerated in Traf5 −/− mice than in wild-type mice 27 , which indicates that TRAF5 limits T cell-mediated inflammatory diseases such as asthma and suggests that TRAF5 has a function that has not been delineated in detail in T cells. However, it is unclear how TRAF5 negatively regulates the signaling and inflammatory responses mediated by CD4 + T cells.
In this study, we found that after receiving signal 1 and signal 2 in the presence of signal 3 from IL-6, naive Traf5 −/− CD4 + T cells produced more IL-17 than did their wild-type counterparts and developed a pronounced T H 17 phenotype both in vitro and in vivo. In accordance with that, Traf5 −/− mice showed enhanced clinical signs of experimental autoimmune encephalomyelitis (EAE), and Traf5 −/− CD4 + T cells a r t i c l e s induced exaggerated EAE in TRAF5-sufficient recipient mice. We also found that TRAF5 constitutively associated with gp130 and negatively controlled IL-6-STAT3 signaling. Our data demonstrate that TRAF5 regulates signal 3 in CD4 + T cells and works as an anti-inflammatory factor to limit immune responses mediated by effector CD4 + T cells that had been primed with IL-6.
RESULTS

TRAF5 deficiency facilitates IL-6-driven T H 17 differentiation
To investigate how TRAF5 regulates the differentiation of CD4 + T cells, we cultured highly purified naive T cells from wild-type or Traf5 −/− C57BL/6 (B6) mice in polarizing cytokine conditions (Fig. 1) . After culturing naive T cells for 3-5 d in plates coated with antibody to the invariant signaling protein CD3 (anti-CD3) and antibody to the coreceptor CD28 (anti-CD28), we stained the cells for intracellular interferon-γ (IFN-γ), IL-4, IL-17A and the transcription factor Foxp3 to assess development of the T H 1, T H 2, T H 17 and regulatory T cell (T reg cell) subsets, respectively. Notably, when we added IL-6 to the cultures, the proportion of Traf5 −/− CD4 + T cells that expressed IL-17A was significantly higher than that of wild-type CD4 + T cells (Fig. 1a) . T H 17 cell-associated genes, such as Rorc, Il17a, Il17f and Il23r, were also significantly upregulated in Traf5 −/− T cells (Fig. 1b) , and IL-17A and IL-21 were much more abundant in Traf5 −/− cultures than in wild-type cultures, but IFN-γ was not (Fig. 1c) . Naive Traf5 −/− CD4 + T cells expressed the same amount of IL-6R-gp130 as wild-type naive CD4 + T cells did (Supplementary Fig. 1a ). In these polarized (Fig. 1a) or Tbx21, Gata3 or Foxp3 mRNA (Supplementary Fig. 1b) . Expression of Traf5 mRNA in wild-type CD4 + T cells was significantly downregulated after stimulation with anti-CD3 and anti-CD28, and this was not affected much by the presence of exogenous cytokines (Supplementary Fig. 1c ). Wild-type and Traf5 −/− CD4 + T cells proliferated and produced IL-2 in response to anti-CD3 and anti-CD28 in an equivalent manner 27 (data not shown). These results demonstrated that TRAF5 in CD4 + T cells negatively regulated the IL-6-mediated development of T H 17 cells.
In agreement with results reported above, enhanced T H 17 development was also induced by stimulation of Traf5 −/− CD4 + T cells with soluble anti-CD3 and splenic antigen-presenting cells (APCs) from wild-type B6 mice (Fig. 1d) . Moreover, in the same culture, the development of Foxp3-expressing T cells was suppressed in the absence of TRAF5 (Fig. 1d) . This supported the findings that IL-17 + CD4 + T cells and Foxp3 + CD4 + T cells were reciprocally regulated during differentiation and that signaling via IL-6 controls the downregulation of Foxp3 expression 31 .
Next, to evaluate more precisely the role of TRAF5 in T H 17 differentiation, we obtained naive CD4 + T cells from wild-type or Traf5 −/− OT-II mice (which have transgenic expression of an ovalbumin (OVA)-specific TCR) and cultured the cells with a low dose of OVA peptide (amino acids 323-339) and splenic APCs from wild-type B6 mice in the presence or absence of IL-6. The primary production of IL-17A and IL-21 was significantly higher in Traf5 −/− OT-II cultures than in wild-type cultures (Fig. 2a) . Recall IL-17A expression in primed Traf5 −/− OT-II cells was additionally about twofold higher than that in wild-type cells (Fig. 2b) . Proliferative responses to antigen and IL-6 ( Supplementary Fig. 2a,b) , endogenous IL-6 production in the T cell culture ( Supplementary  Fig. 2c ) and susceptibility to growth arrest mediated by transforming growth factor-β (TGF-β) (Supplementary Fig. 2d ) were similar in the two groups. Thus, these results substantiated the results presented above showing enhanced T H 17 differentiation of polyclonal T cells in the absence of TRAF5 and suggested that TRAF5 regulated IL-6 signaling but not cell proliferation, IL-6 production or TGF-β signaling.
To determine whether TRAF5 serves a similar function in vivo, we adoptively transferred naive wild-type or Traf5 −/− OT-II T cells into congenic B6 mice, followed by subcutaneous immunization of the recipient mice with OVA protein in complete Freund's adjuvant (CFA). We then assessed recall IL-17 responses in donor OT-II cells in the draining lymph nodes 7 d after immunization (Fig. 2c) . IL-17A + Traf5 −/− OT-II cells were about two times more abundant than IL-17A + wild-type OT-II cells, in both frequency and absolute number (Fig. 2c) . Collectively, these results demonstrated that TRAF5 antagonized the differentiation of T H 17 cells both in vitro and in vivo. (Fig. 3a) . IL-6-IL-6R promoted the phosphorylation of STAT3 in a dose-dependent way (Fig. 3b) , and the response peaked at 10 min, then decreased (Fig. 3c) . Notably, under these conditions, Traf5 −/− CD4 + T cells displayed significantly larger amounts of phosphorylated STAT3 than did their wild-type counterparts ( Fig. 3b-d) . Traf5 −/− CD8 + T cells also showed enhanced phosphorylation of STAT3 mediated by IL-6 ( Supplementary Fig. 3a) , which indicated that this TRAF5 function was not specific to CD4 + T cells. However, expression of Traf5 mRNA or Il6st mRNA (which encodes gp130) was significantly lower in other cell populations, such as B cells, natural killer T cells, natural killer cells and macrophages, than in T cells ( Supplementary Fig. 3b,c) , and IL-6-mediated phosphorylation of STAT3 in Traf5 −/− macrophages was similar to that in wildtype macrophages (Supplementary Fig. 3d ). Thus, TRAF5 may not be important for signaling via IL-6 in cells with lower expression of TRAF5 or gp130. The phosphorylation of STAT3 mediated by IL-10 or IL-21 was not affected by TRAF5 deficiency (Supplementary Fig. 3e,f) , which confirmed the specificity of these results. Collectively, these results suggested that TRAF5 antagonized an early signaling activity downstream of gp130 in T cells.
Binding of TRAF5 to gp130 antagonizes recruitment of STAT3
To explore the molecular mechanism by which TRAF5 inhibited the activation of STAT3, we transfected HEK293T human embryonic kidney cells to express both c-Myc-tagged gp130 and V5-tagged TRAF5 (Fig. 4a) . Notably, we detected a constitutive association between TRAF5 and gp130 in primary CD4 + T cells (Fig. 4b) , which showed that the binding of TRAF5 to gp130 was physiologically relevant. The TRAF-C domain is responsible for binding to the cytoplasmic tails of members of the TNFRSF; thus, this domain of TRAF5 might be critical for its association with gp130. To assess this, we transfected HEK cells to express gp130 together with either the amino terminus of TRAF5 (amino acids 1-241), which contains RING and zincfinger domains (TRAF5 (1-241) ), or the carboxyl terminus of TRAF5 (amino acids 242-558), which contains leucine-zipper and TRAF-C domains (TRAF5(242-558)). As expected, TRAF5(242-558) immunoprecipitated together with gp130 (Fig. 4c) . The finding that TRAF5 did not need its RING or zinc-finger domains to interact with gp130 indicated that TRAF5(242-558) might antagonize the IL-6-mediated recruitment of STAT3 to gp130. To investigate this, we transfected HEK cells to express gp130 and STAT3 in the presence or absence of TRAF5(242-558) and evaluated the binding of STAT3 to gp130 by immunoprecipitation. After stimulation with IL-6-IL-6R, STAT3 was recruited to gp130, and that recruitment was strongly suppressed by the expression of TRAF5(242-558) (Fig. 4d) . In addition, the amount of TRAF5 associated with gp130 increased further after stimulation with IL-6-IL-6R (Fig. 4d) . Collectively, these results demonstrated that constitutive binding of TRAF5 to gp130 was antagonistic for IL-6-driven recruitment of STAT3 to gp130.
To map the cytoplasmic region of gp130 necessary for binding TRAF5, we prepared five deletion mutants of gp130 (mutants 2-6) that differed in the length of their cytoplasmic tail ( Supplementary  Fig. 4a ). The ability of TRAF5(242-558) to bind gp130 was much lower for gp130 mutants 3, 4, 5 and 6 ( Supplementary Fig. 4a ), which indicated that amino acid residues 774-848 of gp130 were critical for binding. To investigate this further, we prepared four more mutants of gp130 (mutants 7-10) with various deletions in the cytoplasmic region from residue 774 to residue 848 (Fig. 4e) . The gp130 mutants 7 and 8 displayed lower binding to TRAF5(242-558) (Fig. 4e) , which indicated that amino acids 774-798 of gp130 were critical for this binding. That region in gp130 contains a 'Ser-X-X-Glu' motif (where 'X' indicates any amino acid; site 1, Ser-Arg-Ser-Glu) and two diacidic amino acids (site 2, Glu788-Glu789 and Glu792-Asp793) (Fig. 4f) , which are recognition elements for the TRAF-C domain [32] [33] [34] . To investigate whether those motifs were critical for binding to TRAF5, we prepared mutants of gp130 with substitution of alanine for other amino acids (Fig. 4f,g ). The gp130 mutant with substitutions in site 1 (AAAA, positions 746-779) or in site 2 (AARPAA, positions 788-793) showed considerably diminished binding to TRAF5(242-558) relative to that of wild-type gp130 (Fig. 4f) . In contrast, the binding of gp130 mutants 12 (AARPED, positions 788-793) and 13 (EERPAA, positions 788-793) was similar to that of wild-type gp130 (Fig. 4g) , which indicated that either of the two diacidic motifs in gp130 site 2 was necessary for the association of gp130 with TRAF5. Collectively, we concluded that both Ser-Arg-Ser-Glu (positions 746-779) and Glu-Glu-Arg-Pro-Glu-Asp (positions 788-793) in the cytoplasmic tail of gp130 were essential for its recognition by TRAF5. We found that those regions in gp130 are highly conserved across various species (Supplementary Fig. 4b ).
TRAF5-gp130 binding negatively controls T H 17 differentiation
To determine whether the carboxy-terminal domain of TRAF5 is inhibitory for T H 17 differentiation, we cultured naive Traf5 −/− CD4 + T cells in polarizing conditions with IL-6, transduced differentiating T cells with a retroviral vector encoding green fluorescent protein (GFP) and TRAF5(1-558), TRAF5(1-241) or TRAF5(242-558), and assessed the frequency of IL-17A + cells in the GFP + CD4 + gated population. TRAF5(1-558) and TRAF5(242-558) significantly suppressed the development of IL-17A-expressing T cells, but TRAF5(1-241) did not (Fig. 5a) . Thus, the carboxy-terminal domain of TRAF5 served an inhibitory role in IL-6-mediated T H 17 development.
The finding that both site 1 and site 2 in gp130 (Fig. 4f) were responsible for its binding to TRAF5 raised the possibility that expression of a peptide containing those amino acid residues might inhibit Fig. 4c,d ). As expected, GFP-gp130(769-800) immunoprecipitated together with TRAF5(242-558), but mutant GFP-gp130(769-800) with substitution of alanine for various amino acids in gp130 did not ( Supplementary  Fig. 4c ), and expression of GFP-gp130(769-800) inhibited the binding of gp130 to TRAF5(242-558) (Supplementary Fig. 4d) . Thus, these results demonstrated that GFP-gp130(769-800) competitively inhibited the binding of TRAF5 to gp130. To elucidate how endogenous binding of TRAF5-gp130 affected T H 17 differentiation, we transduced differentiating wild-type or Traf5 −/− CD4 + T cells with retroviral vector encoding GFPgp130(769-800) with wild-type sequence (VPSVQVFSRSESTQPLL DSEERPEDLQLVDSV; underlining indicates sequence altered in the mutant) or the mutant GFP-gp130(769-800) described above with substitution to alanine (VPSVQVFAAAASTQPLLDSAARPAALQL VDSV). GFP-gp130(769-800) with wild-type sequence significantly enhanced the generation of IL-17A-producing wild-type CD4 + T cells relative to that elicited by control vector or the mutant GFPgp130(769-800) (Fig. 5b) . We did not detect such activity in Traf5 −/− CD4 + T cells (Fig. 5b) . These results indicated that intracellular expression of a peptide containing both site 1 and site 2 in gp130 augmented IL-6-driven T H 17 differentiation through the sequestration of endogenous TRAF5 away from gp130.
TRAF5 deficiency in CD4 + T cells exacerbates EAE
Finally, to investigate TRAF5 function in an IL-6-dependent disease model 35 , we immunized groups of Traf5 −/− B6 mice and their wild-type littermates with a peptide of amino acids 35-55 myelin oligodendrocyte glycoprotein (MOG) emulsified in CFA on day 0, to induce EAE. We collected draining lymph nodes from wild-type and Traf5 −/− mice on day 8 and restimulated those nodes with the MOG peptide to measure recall cytokine responses. IFN-γ and IL-17 responses in Traf5 −/− cells from draining lymph nodes were higher than those in their wild-type counterparts (Fig. 6a) ; IL-4 and IL-10 were below the limit of detection (data not shown). Clinical signs of disease were evident on day 11 and peaked between days 14 and 18 (Fig. 6b) . Traf5 −/− mice developed EAE with kinetics similar to that of wild-type mice but with a considerably higher clinical score (Fig. 6b) and more body-weight loss (Supplementary Fig. 5a ) than that of wild-type mice. The accumulation of IFN-γ + CD4 + T cells and IL-17 + CD4 + T cells in the central nervous system on day 23 was also much greater in Traf5 −/− mice (Fig. 6c) . Although not only T H 17 responses but also T H 1 responses were enhanced in Traf5 −/− mice (Fig. 6c) , these results demonstrated that TRAF5 limited the generation of pathogenic MOG-specific T cells responsible for the induction of EAE. IFN-γ-producing cells may develop from IL-17-producing cells ('ex-T H 17 cells') after receipt of other inflammatory signals 35, 36 .
To substantiate the hypothesis that the enhanced EAE responses noted above were caused by TRAF5 deficiency in CD4 + T cells, we adoptively transferred wild-type or Traf5 −/− CD45.2 + CD4 + T cells into congenic CD45.1 + B6 mice that had been sublethally irradiated, then immunized the recipient mice with the MOG peptide noted above in CFA on day 0 (Fig. 6d) . At day 7, we detected donor CD45.2 + CD4 + T cells in the peripheral blood of recipient mice, and the frequency of Traf5 −/− donor cells was similar to that of wild-type cells ( Supplementary Fig. 5b) ; this indicated that both genotypes of donor T cells populated the periphery equivalently. Recipients of Traf5 −/− CD4 + T cells had significantly higher EAE scores than those of recipients of wild-type CD4 + T cells (Fig. 6d) . We observed no signs of EAE in mice not been given injection of donor CD4 + T cells during this experimental period (Fig. 6d) . Thus, TRAF5 limited the differentiation of pathogenic T cells responsible for EAE in a CD4 + T cell-intrinsic manner. Collectively, these results demonstrated that TRAF5 served as an important regulator for IL-6 signaling to limit the differentiation of proinflammatory CD4 + T cells.
DISCUSSION
In this study we found that the adaptor TRAF5 constitutively associated with the signal-transducing receptor gp130 in CD4 + T cells, which inhibited the IL-6-mediated activation of STAT3. Thus, TRAF5 limited the differentiation of naive CD4 + T cells into inflammatory effector T cells that received 'instructive' IL-6 signaling during the course of their development. Our results have identified a previously unknown antiinflammatory activity for TRAF5 that is relevant for autoimmune and inflammatory diseases that are driven by pathogenic CD4 + T cells. 
r t i c l e s
The physiological function of TRAF5 has remained elusive since its discovery. Although TRAF5 can act as a proinflammatory mediator downstream of some receptors 25, 26, 28, 37, 38 , several studies have suggested that TRAF5 also functions as an anti-inflammatory factor. After systemic immunization with OVA in alum adjuvant, Traf5 −/− mice show greater susceptibility to the development of an asthma-like phenotype when challenged via the airway with aerosolized OVA, with enhanced airway hyper-responsiveness to methacholine, eosinophilic infiltration in their lungs, IL-5 and IL-13 in their bronchoalveolar lavage fluid, and OVA-specific immunoglobulin E in their plasma 27 . In the present study, when we immunized mice subcutaneously with MOG peptide (amino acids 35-55) in CFA, Traf5 −/− mice developed much more severe clinical signs of EAE than did their wild-type counterparts, with greater infiltration of IL-17-and IFN-γ-producing CD4 + T cells into central nervous system. In addition to that, TRAF5-sufficient wild-type B6 mice given adoptive transfer of Traf5 −/− CD4 + T cells also developed much more severe clinical signs of EAE than those of their counterparts given wild-type cells. These results indicate that TRAF5 in CD4 + T cells negatively regulates the differentiation of proinflammatory helper T cells that are critical for induction of inflammatory diseases.
Although our results support the conclusion that the notably exacerbated EAE phenotype of Traf5 −/− mice was due to pronounced induction of inflammatory CD4 + T cells, TRAF5 might also control responsiveness of other cells to IL-6. It has been suggested that CD8 + T cells serve some roles in EAE. Traf5 −/− CD8 + T cells exhibit defective primary population expansion of T cells and memory T cell responses in a model of infection with Listeria monocytogenes and are unresponsive to the prosurvival effects of CD27 (ref. 25) , which indicates that TRAF5 is a positive signaling element in CD8 + T cells. Although Traf5 −/− CD8 + T cells showed more phosphorylation of STAT3 than did wild-type CD8 + T cells, the difference was smaller for CD8 + T cells than for CD4 + T cells. Thus, it is unlikely that TRAF5 negatively controls EAE through CD8 + T cell responses. TRAF5 associates with the adaptor MyD88 and the binding partner TAB2 after stimulation via Toll-like receptors and antagonizes the association of TAB2 with TRAF6, which results in inhibition of signaling via Toll-like receptors. B cells from Traf5 −/− mice produce more IL-6 in response to agonists of Toll-like recetors 39 . Those results suggest that B cells in Traf5 −/− mice produce more IL-6 after immunization with CFA, which might contribute to the enhanced IL-17 production by Traf5 −/− CD4 + T cells and more severe EAE disease in Traf5 −/− mice. Although B cells expressed about twofold more Traf5 mRNA than did CD4 + T cells, we did not detect substantial expression of Il6st mRNA (which encodes gp130) or gp130 protein in B cells from wild-type and Traf5 −/− mice, which indicated that TRAF5 might not be critical for IL-6 signaling in B cells. Additional work is needed for full understanding of the role of TRAF5 in cells other than CD4 + T cells and the universal role of the TRAF5-gp130 interaction in the context of inflammatory diseases.
Our original hypothesis was that the inhibitory activity of TRAF5 was derived from the modulation of signaling from a member of the TNF family. Many members of the TNFR superfamily, such as the T cell-costimulatory receptor OX40 (CD134), recruit TRAF5 to their intracellular domains 40, 41 , and there is enhanced generation of T H 2 cells driven by OX40 signaling in the context of a deficiency in TRAF5, indicative of direct regulatory activity 27 . We have also observed that an agonistic antibody to OX40 induced more production of IL-17 and IL-21 from antigen-responding Traf5 −/− CD4 + T cells, but that was additionally accompanied by more production of IL-6 (data not shown). Because IL-6 has been linked to IL-17, IL-21 and the induction of T H 2 differentiation, that suggested that IL-6 signaling might be affected mainly by TRAF5 deficiency. In agreement with that, exogenous IL-6 induced more production of IL-17 and IL-21 by Traf5 −/− CD4 + T cells and more phosphorylation of STAT3 in Traf5 −/− CD4 + T cells. That does not rule out the possibility of a role for TRAF5 in signaling from OX40 or other proteins of the TNFR family, but an inhibitory role during IL-6R signaling would provide a logical explanation for the enhanced differentiation of Traf5 −/− CD4 + T cells into the T H 2 and T H 17 lineages. STAT3 is activated during T H 2 differentiation, and by directly binding to T H 2 cell-associated loci, STAT3 facilitates the ability of STAT6 to bind target genes, such as the gene encoding GATA-3, which supports optimal commitment to T H 2 differentiation 12 . STAT3 also regulates the expression of various genes encoding molecules essential for T H 17 differentiation, such as Rorc, Il17a, Il17f, Il21, Il6ra and Il23r 6,9,42 . In our study, a pronounced T H 17 response was induced in the absence of TRAF5 both in vitro and in vivo. In EAE experiments, however, not only T H 17 responses but also T H 1 responses were enhanced in Traf5 −/− mice. During the development of EAE, MOGspecific T H 17 cells rapidly lose IL-17A and produce IFN-γ instead 36 . That might explain why TRAF5 deficiency also resulted in greater T H 1 responses in this model.
Providing a molecular explanation for why TRAF5 modulates T H 2 and T H 17 differentiation, we identified a previously unknown interaction between TRAF5 and gp130. TRAF5 needs its carboxyterminal domain but not its amino-terminal RING or zinc-finger domain for binding with gp130. The TRAF-C domain associates with a wide variety of cytoplasmic proteins, including members of the TNFR superfamily 14, 32 . The region of gp130 that interacts with the TRAF5-C domain has been mapped to the amino acid sequence VFSRSESTQPLLDSEERPEDLQLVD at positions 774-798. That region has been further subdivided into site 1 (Ser-Arg-Ser-Glu; positions 776-779) and site 2 (Glu-Glu-Arg-Pro-Glu-Asp; positions 788-793). Site 1 contains a 'Ser-X-X-Glu' motif, and site 2 contains two diacidic amino acids (Glu788-Glu789 and Glu792-Asp793), both of which are binding motifs for the TRAF-C domain [32] [33] [34] . In general, most TRAF proteins, including TRAF5, already exist as trimers in the cytosol before recruitment to the cytoplasmic tails of molecules of the TNFR family, and the proximity of cytoplasmic tails of those receptors is required for the binding of those receptors to TRAF proteins 33 . Thus, it is reasonable to conclude that the two TRAF-binding sites in close proximity in gp130 are critical for the constitutive association of TRAF5 with gp130 and that the newly formed four TRAF-binding sites in dimerized gp130 efficiently recruit an additional TRAF5 molecule to gp130. In line with the enhanced responses of Traf5 −/− T cells to IL-6, we found that the interaction between the TRAF5-C domain and gp130 antagonized the interaction of gp130 with STAT3 and inhibited the development of T H 17 cells. STAT3 binds to the four distal phosphorylated-tyrosine motifs of gp130: Tyr-Arg-HisGln, Tyr-Phe-Lys-Gln, Tyr-Lys-Pro-Gln and Tyr-Met-Pro-Gln (with phosphorylated tyrosine at positions 765, 812, 904 and 914, respectively) 43 . The TRAF5-binding region is located between those first two motifs, which suggests that TRAF5 inhibits the recruitment of STAT3 to these two phosphorylated-tyrosine motifs through steric hindrance in gp130 or through modulation of an optimal configuration of gp130 that might be required for binding STAT3. Additional biochemical analyses are essential for understanding the structurefunction relationship of the TRAF5-gp130 interaction. The dileucine internalization motif in gp130 (Lue784-Lue785) serves a role in the ligand-independent internalization of gp130 (refs. 4,44) . The TRAF5-binding region identified in our study contained that motif; thus, npg the TRAF5-gp130 interaction might influence the internalization of gp130. However, we found that increasing or decreasing the expression of TRAF5 did not affect the amount of gp130 on the cell surface (data not shown), which suggests this is not the mechanism by which TRAF5 alters gp130 activity.
In summary, our results have revealed an unexpected molecular function for TRAF5. The interaction between TRAF5 and gp130 limited IL-6R-gp130-dependent activation of STAT3 and suppressed STAT3-dependent gene transcription, which controls the extent of effector CD4 + T cell development and can restrain the pathogenesis of autoreactive CD4 + T cells in inflammatory and autoimmune diseases. Our data showing that TRAF5 inhibited proinflammatory IL-6R signaling in CD4 + T cells have identified a previously unknown mechanism for controlling helper T cell differentiation and highlight a regulatory event in a wide range of inflammatory responses mediated by effector CD4 + T cells.
METHODS
Methods and any associated references are available in the online version of the paper. 
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